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Introduction: Mediastinal lymphadenopathy in patients with an
extrathoracic malignancy is a common clinical scenario. Invasive
sampling of intrathoracic lymph nodes may be performed by medi-
astinoscopy or endoscopic ultrasound-guided fine needle aspiration.
Endobronchial ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA) is an alternative to mediastinoscopy and endoscopic
ultrasound in patients with lung cancer and sarcoidosis. The utility
of EBUS-TBNA in patients with extrathoracic malignancy was
evaluated.
Methods: Consecutive patients who were suspected to have in-
trathoracic lymph node metastases from an extrathoracic malig-
nancy underwent EBUS-TBNA. When EBUS-TBNA did not pro-
vide a specific diagnosis, patients underwent mediastinoscopy or
clinical follow-up of at least 6 months duration.
Results: One hundred sixty-one patients meeting the inclusion
criteria underwent EBUS-TBNA in five UK centers over a 3-year
period. EBUS-TBNA diagnosed mediastinal or hilar metastases in
71 (44%) patients, new lung cancer in 20 (12%) patients, and
sarcoidosis in 14 (9%) patients. The sensitivity, negative predic-
tive value for malignancy, and overall accuracy for EBUS-TBNA
were 87%, 73% and 88%, respectively. One hundred ten (68%)
patients in the study had a final diagnosis of malignant intratho-
racic lymphadenopathy.
Conclusion: Because of the high prevalence of alternative diagno-
ses, pathological evaluation is important in patients with extratho-
racic malignancy and suspected mediastinal or hilar lymph node
metastases. EBUS-TBNA is a safe and sensitive technique and may
be considered a first-line investigation in these patients.
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(J Thorac Oncol. 2011;6: 1505–1509)
Mediastinal lymphadenopathy is a common finding inpatients with extrathoracic malignancies and is a fre-
quent diagnostic dilemma for respiratory physicians and on-
cologists. Enlarged mediastinal nodes are often discovered at
the time of initial staging when the demonstration of medi-
astinal metastases may significantly alter treatment and prog-
nosis. Alternatively, mediastinal lymphadenopathy may be
discovered after treatment and require pathological evalua-
tion to exclude or confirm disease recurrence.
Before the advent of endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA), sampling of
intrathoracic lymphadenopathy was most commonly per-
formed by mediastinoscopy or endoscopic ultrasound-guided
fine needle aspiration (EUS-FNA). However, mediastinos-
copy is associated with a 1% complication rate1 and require-
ment for general anesthesia, whereas EUS-FNA does not
allow access to the right paratracheal and hilar lymph nodes.2
EBUS-TBNA allows sampling of paratracheal, subcarinal,
and hilar lymphadenopathy under sedation in the outpatient
setting. The technique has an established role in the diagnosis
and staging of lung cancer with a sensitivity of more than
90%, even early in the learning process.3 Prospective data are
now available on the utility of EBUS-TBNA in the diagnosis
of sarcoidosis,4,5 and a small series has also demonstrated a
high diagnostic yield in patients with tuberculous lymphade-
nopathy.6 Limited data, however, exist on the role of EBUS-
TBNA in the diagnosis of extrathoracic malignancies.7 In this
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large multicenter study, we describe the diagnostic utility of
EBUS-TBNA for the clarification of intrathoracic lymphade-
nopathy in patients with extrathoracic malignancy.
PATIENTS AND METHODS
Participants
Consecutive patients with an active or previous diag-
nosis of extrathoracic malignancy and enlarged intrathoracic
lymphadenopathy who underwent EBUS-TBNA between
January 1, 2007, and December 1, 2010, were included.
Patients were suspected to have intrathoracic lymph node
metastases on the basis of computed tomography or positron
emission tomography-computed tomography findings. The par-
ticipating centers were University College London Hospital,
Papworth Hospital, Cambridge, University Hospitals Birming-
ham, University Hospital of North Tees, and Lancashire Teach-
ing Hospitals, Preston. The observational design of the study
meant that ethical approval was not required.
Procedure
EBUS-TBNA was performed with a dedicated linear
echo-endoscope (Olympus BF-UC160F-OL8) under moder-
ate sedation with intravenous midazolam and fentanyl or
midazolam alone. Systematic assessment of all EBUS acces-
sible lymph nodes was made. Vascular structures were
avoided using the Doppler function. Under direct ultrasound
guidance, the lymph node was then aspirated using either a
21-gauge or 22-gauge needle. Samples were expelled both
onto glass slides where air-dried smears were made for
cytology and also into liquid fixative suitable for cell block
preparations. In cases where core biopsies were obtained for
histology, these were placed directly into formalin. The
appropriate immunohistochemical staining with antibodies to
the cytokeratins, thyroid transcription factor-1, prostate-spe-
cific antigen, estrogen and progesterone receptors, and neu-
roendocrine markers, was used when required.
Statistical Analysis
Standard definitions of sensitivity, negative predictive
value (NPV), and diagnostic accuracy were used. Positive
malignant findings on EBUS-TBNA were not confirmed, and
specificity was assumed to be 100%. Nonmalignant findings
at EBUS-TBNA were subject to surgical confirmation or at
least 6 months of radiological and clinical follow-up. Predic-
tors of malignant lymphadenopathy were modeled using
logistic regression. Continuous variables were not catego-
rized in the regression analyses. Significant variables in
univariate analysis (at the 10% level) or those deemed clin-
ically important were included in the multivariate model.
Analysis was carried out with STATA version 10 (Stata
corporation). This study conforms to the standards for the
reporting of diagnostic accuracy studies initiative.8
RESULTS
All 161 patients successfully underwent EBUS-TBNA
and no complications were observed. The median age of the
patients was 64 (range 19–86) years. The most common
extrathoracic malignancies observed were breast, colorectal,
and esophageal carcinomas. The patient characteristics are
summarized in Table 1.
The median size of lymph nodes seen at EBUS-TBNA
was 25 (range 6–48) mm and each node underwent a median
of 4 passes (range 2–6). One hundred ninety-six nodes were
sampled in 160 patients, with no samples taken in one patient.
The subcarinal or right paratracheal lymph node stations were
the site of aspiration in 100 (62%) patients. Twenty-eight
(17%) patients had only hilar lymph nodes sampled. The
sensitivity, NPV for malignancy, and overall accuracy for
EBUS-TBNA were 87%, 73% and 88%, respectively. The
final diagnosis was unknown in six patients. If we assume
that the intrathoracic lymph nodes in these patients harbored
extrathoracic malignancy (undiagnosed by EBUS-TBNA),
the sensitivity, NPV, and accuracy are 78%, 61%, and 84%.
Overall, 110 (68%) of the patients in the study were known to
have had malignant intrathoracic lymphadenopathy. EBUS-
TBNA did not obtain a diagnosis in 13 patients with metas-
tases to intrathoracic nodes from an extrathoracic malig-
nancy. Four patients had breast cancer, one bladder cancer,
one renal cell carcinoma, one seminoma, one leiomyosar-
coma, three melanoma, one head and neck carcinoma, and
one patient had lymphoma.
In 14 (9%) patients, EBUS-TBNA demonstrated
granulomas alone and the final diagnosis in each of these
patients was sarcoidosis. Of the 51 cases, in which EBUS-
TBNA did not provide a malignant or alternative diagno-
sis, surgery was performed in 9 (18%), and a median of 15
months of clinical and radiological follow-up was used in
the remainder (Figure 1).
Univariate analysis of lymph node size, number of
passes per node, and number of lymph nodes sampled
revealed that there was a statistically significant associa-
TABLE 1. Patient Characteristics
Total No. of Patients 161
Male 73 (45%)
Median age (range), yr 64 (19–86)
Median lymph node size (range), mm 25 (6–48)
Extrathoracic malignancy primary site
Breast 40
Colorectal 25
Esophagus 13
Melanoma 12
Head and neck 11
Renal cell 10
Prostate 9
Bladder 8
Lymphoma 7
Ovarian 5
Sarcoma 4
Testis 3
Cervix 3
Stomach 3
Endometrial 2
Penis 2
Teratoma, anus, vulva, schwannoma 1 each
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tion between lymph node size and presence of metastatic
lymphadenopathy (p  0.03). In the logistic regression
multivariate model, lymph node size remained signifi-
cantly associated with malignant lymphadenopathy (OR
1.04, 95% confidence interval 1.00–1.08). This implies
that for every increase in lymph node size of 1 mm, the
probability of the lymph node being malignant increases
by 4%. Univariate analysis demonstrated that there was no
association between lymph node size and yield from
EBUS-TBNA (p  0.279).
Of the 71 patients with extrathoracic malignancy diag-
nosed by EBUS-TBNA, morphological appearances alone
were sufficient in 17 (24%). Immunohistochemistry was
successfully performed in 54 (76%) patients whose EBUS-
TBNA had diagnosed malignancy, elucidating the primary
origin of the tumor (Figure 2).
DISCUSSION
This multicenter study of 161 patients is the largest to
date to demonstrate the role of EBUS-TBNA in the diagnosis
of intrathoracic lymphadenopathy in patients with extratho-
racic malignancy. EBUS-TBNA demonstrated a sensitivity of
87% with an overall diagnostic accuracy of 88% and there-
fore is an important alternative to other techniques for the
diagnosis of intrathoracic lymphadenopathy in patients with
extrathoracic malignancy.
Clarification of mediastinal lymphadenopathy in the
context of a known or suspected extrathoracic malignancy is
a common scenario faced by physicians and may have pro-
found effects on the patient’s treatment and prognosis. Al-
though mediastinoscopy is considered the gold standard in-
vestigation in this clinical scenario, mediastinoscopy is
associated with risks due to general anesthesia, a serious
complication rate of 1% and increased healthcare costs com-
pared with minimally invasive techniques. Standard cervical
mediastinoscopy also only provides access to the paratracheal
and anterior subcarinal lymph nodes. Evidence of the utility
of alternatives to mediastinoscopy in this patient group is
beginning to emerge. A recent report of conventional TBNA
in five patients with extrathoracic malignancy9 showed that
the procedure is able to provide suitable material for the
diagnosis of extrathoracic malignancy. A large study of 75
patients undergoing EUS-FNA demonstrated a sensitivity of
86%,10 whereas Tournoy et al.7 also showed a sensitivity of
85% for EBUS-TBNA in 61 patients with malignant intratho-
racic lymphadenopathy.
In this study of 161 patients with suspected metas-
tases from extrathoracic malignancy, only 84 (52%) had a
final diagnosis of intrathoracic lymph node metastases,
highlighting the importance of pathological confirmation
in this clinical scenario. The NPV obtained in this cohort
was low at 73%, emphasizing the need for further inves-
FIGURE 1. Flowchart of patients.
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tigation if EBUS-TBNA did not yield a malignant or other
specific diagnosis.
Of note in this study, EBUS-TBNA demonstrated non-
caseating granulomas in 14 cases, in all of whom a sarcoid-
like reaction was the final diagnosis. Previous studies of
granulomas in mediastinal lymph nodes in patients with
early-stage non-small cell lung cancer have suggested that
this finding reliably excludes malignancy and suggested that
clinical follow-up rather than further invasive sampling may
be justified in this context.11 The statement that the presence
of granulomas may reliably exclude malignancy is question-
able. The coexistence of granulomas and malignant cells in
metastatic lymph nodes has been described,12 and, although
we did not encounter this phenomenon in any of our patients
initially diagnosed with sarcoid on EBUS TBNA, we would
recommend further investigation when granulomas only are
observed in EBUS-TBNA and the suspicion of malignancy
remains.
Limitations of this study are recognized. The retro-
spective nature means that only patients who were clini-
cally selected for EBUS-TBNA were included. Although
consecutive patients were included to minimize this bias,
the characteristics of patients who were directly referred for
mediastinoscopy outside of the study are unknown. The multi-
center collaboration strengthens conclusions about the general-
izability of the data; however, due to differing pathology prac-
tices, standardized immunohistochemistry protocols were not
followed.
In conclusion, pathological evaluation is important for
diagnosis and staging of patients with extrathoracic malig-
nancy and suspected mediastinal or hilar lymph node metas-
tases. EBUS-TBNA is a safe and sensitive technique and may
be considered a first-line investigation in these patients.
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